AbbVie invests $380M in two new API facilities, adding 300 jobs as part of its $100B U.S. pledge. Targets obesity and neuroscience drugs by 2029.

AbbVie Doubles Down on U.S. Manufacturing with $380 Million API Investment

AbbVie pledges $100B in U.S. investment for 3-year tariff exemption. Humira, Synthroid join TrumpRx. Only Regeneron remains outside Trump's pharma pricing deals.

AbbVie Signs $100 Billion Deal With Trump, Clearing Path for Humira on TrumpRx

AbbVie pays $650M upfront for RemeGen's PD-1/VEGF bispecific RC148, joining Pfizer, Merck and BioNTech in the race to dethrone Keytruda.

AbbVie (ABBV)·Earnings Reports

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Analyst Coverage

Recent News about AbbVie

AbbVie Doubles Down on U.S. Manufacturing with $380 Million API Investment

AbbVie Signs $100 Billion Deal With Trump, Clearing Path for Humira on TrumpRx

AbbVie Pays $650M to Join PD-1/VEGF Bispecific Race in JPM's First Big Deal

AbbVie Nears $20B+ Deal for Revolution Medicines, Capping Historic RAS Rally